SEC Settles Insider Trading Suit Over Pharma Deal

Law360, New York (September 2, 2010, 6:41 PM EDT) -- A former hedge fund manager and an executive with a New Jersey-based pharmaceutical company, both facing insider trading charges tied to AstraZeneca’s acquisition of MedImmune Inc. in 2007, have agreed to settle a U.S. Securities and Exchange Commission case against them.

Stephen R. Goldfield, the hedge fund manager, was able to rack up nearly $14 million in illegal profits, thanks to nonpublic information funneled to him by longtime friend and business executive James W. Self Jr., the SEC alleged in a complaint filed Wednesday in the...
To view the full article, register now.